Investing in the
future of biotech

Science at our core.

We provide early-stage smart capital to entrepreneurs pushing the boundaries at the forefront of medicine, biotech and bioengineering.

We are supported by a network of engaged, deeply knowledgeable scientists at world-leading research institutions working at the top of their fields across biology and medicine.

Our thesis.
Scientific Risk-Arbitrage

At Tachyon, we know how to price scientific risk earlier than others.

We maximize upside potential by investing early in disruptive platforms. We mitigate risk by focusing on world-class research with protected IP.
‍

Meet our team

Our focus.

Early-stage

We focus on identifying good science early, and on assessing its potential at different stages of development.

Transformative

We are committed to supporting scientific teams pursuing ambitious goals and transformative technologies at the forefront of medicine, biotech and bioengineering.

Peer-reviewed

We back teams with world-leading published research, who are recognized as leaders in their fields and are at the forefront of their research areas.

IP-backed

We invest in companies with protected IP, developed by or in collaboration with their scientific co-founders.

Explore our portfolio

Chameleon Biosciences

Chameleon’s technology enables the delivery of AAV gene therapies with higher efficacy.
‍

Enclear Therapies

Systems to halt the progression of neurodegenerative diseases by removing toxic proteins.

Mammoth Biosciences

CRISPR-based platform building an extensive variety of tests for bio sensing in healthcare, agriculture, manufacturing, and forensics.

Scipher

Develops tests to predict response to blockbuster drugs & new targeted therapies.
‍

Totient

Disruptive high-throughput drug discovery platform for monoclonal antibodies (mAb)
‍

Peptilogics

Rapidly & effectively developing novel peptide anti-infectives therapeutics.
‍

EpiBone

Digitally designed, made of stem cells, cultivated through bioreactors personalized bone grafts.

TARA

Engineered human cardiac tissues that exhibit unprecedented functional maturity.
‍

DTx Pharma

Their siRNA delivery platform allows for selective choice of therapeutic targets.

Forkhead

Exploiting the natural plasticity of cells in the gut to treat insulin-dependent diabetes.
‍

Quthero

Quthero enables full epithelial restoration via collective migration of cells.
‍

See our full portfolio

Building or investing in biotech?
Get the latest pulse on our companies and industry insights.

Subscribe to our newsletter

Thanks for joining our newsletter
Oops! Something went wrong while submitting the form.